ʻO LUMICKS, kahi ʻoihana ʻepekema ola e hoʻomohala ana i nā mea hana no ka hoʻokalakupua hoʻokahi-molele a me ka nānā ʻana o ka cell avidity, i kēia lā ua hoʻolaha ʻia kahi pepa e wehe ana i nā ʻike hou i ka hana ʻana o Chimeric Antigen Receptor (CAR) T cell i paʻi ʻia i ka pukana o Pepeluali 2022 o Frontiers in Immunology. Hōʻike ka pepa i nā noiʻi hou i hana ʻia ma Kings College London ma lalo o ka mālama ʻana o Dr. John Maher, me ka hui pū ʻana me Leucid Bio, me ka hoʻohana ʻana i LUMICKS 'z-Movi® Cell Avidity Analyzer. Ke hōʻike nei kēia noiʻi hou i ka hoʻohui ʻana i kahi mea hoʻokipa huli lua i nā cell T CAR e hoʻonui i ko lākou hiki ke hoʻopaʻa i nā cell cancer a hōʻike i ka ʻōlelo hoʻohiki e hoʻomaikaʻi i nā immunotherapies no ka maʻi kanesa i nā hiʻohiʻona pre-clinical.
Ua ʻōlelo ʻo Dr. John Maher, Luna Haʻawina Nui ma Kings College London ma ke Kula o Cancer & Pharmaceutical Sciences, a me ka Luna Nui ʻepekema o Leucid Bio, "ʻO nā mana kūʻokoʻa o ka z-Movi Cell Avidity Analyzer i hiki iā mākou ke ana i ka nui o ka ikaika o ka launa pū ʻana. ma waena o kā mākou papa o nā pūnaewele CAR T a me nā maʻi kanesa. Ke hoʻohana nei i ka LUMICKS 'z-Movi mea kani, hiki iā mākou ke ʻimi maʻalahi i nā CARs 'goldilocks' ʻaʻole naʻe e hoʻopaʻa ikaika a nāwaliwali paha i nā cell target a hōʻike i ka pepehi maikaʻi ʻana i nā hiʻohiʻona pre-clinical. Hiki i nā ʻike hou i loaʻa me ka hoʻohana ʻana i nā ana avidity cell ke kōkua maoli i ka hoʻomaikaʻi ʻana i ke ʻano o kā mākou hoʻolālā ʻana i nā lāʻau lapaʻau.
Hoʻohui ʻia ʻo Andrea Candelli, Luna Nui ʻepekema o LUMICKS, "Ke kaʻana like nei mākou i ka hauʻoli o ka hui ʻo Kings College e pili ana i nā hōʻike hou i hōʻike ʻia e kēia pepa o ke kuleana koʻikoʻi o ka avidity cell i ka wehe ʻana a me ka hoʻonui ʻana i nā cell T CAR. ʻO ka noiʻi ikaika a Dr. Maher e hōʻike ana i nā ʻike e hiki ai i kā mākou ʻenehana kipi ke kōkua i nā mea noiʻi a puni ka honua e ʻike, a kōkua i ka ʻepekema e hoʻoponopono maikaʻi i nā pilikia koʻikoʻi i ke olakino kanaka, ʻoi aku ka hoʻolālā ʻana i nā immunotherapies ʻoi aku ka maikaʻi e hakakā ai i ka maʻi kanesa.
Hoʻololi ka immunotherapies cell CAR-T i nā pūnaewele T i loko o ka ʻōnaehana pale e hoʻopaʻa a luku i nā pūnaeau maʻi maʻi ma o ka hoʻoponopono hou ʻana i nā cell T e hana i ka protein CAR, kahi e hoʻopaʻa ai nā pūnae T i, a hoʻouka i nā maʻi maʻi maʻi. Hāʻawi ʻia ia mau lāʻau lapaʻau ma ke ʻano he lapaʻau no kekahi mau maʻi maʻi maʻi a he nui nā mea noiʻi, me Kauka Maher, ke noiʻi nei i nā hoʻolālā hou no ka CAR T-cell therapy no nā maʻi maʻi maʻi ʻaʻai paʻa.
ʻO ka z-Movi ke ana i ka avidity, a i ʻole ka pae o ka hoʻopaʻa ʻana, ma waena o nā cell immune e like me CAR Ts, a me kā lākou mau pahuhopu, nā cell cancer, e hiki ai i nā mea noiʻi ke ʻike i nā cell immunotherapeutic effector ikaika loa ma ke ʻano he poʻe moho e hoʻopaʻa a luku i nā pūnaewele maʻi maʻi. Hāʻawi kēia ʻenehana hou i nā hualoaʻa wānana, reproducible, a wikiwiki hoʻi i ka hoʻonā hoʻonā hoʻokahi kelepona me ka ʻole o ka hoʻopaʻapaʻa ʻana i ka cell viability, a hōʻoia i ka mālama ʻana i ka laʻana. Hoʻohana ka LUMICKS 'cell avidity solutions i nā acoustics e ana i nā ikaika a me nā pilina ma waena o nā pūnaewele, me ka pahuhopu e hoʻopōkole i ka pōʻai hoʻomohala lāʻau no nā hoʻomaʻamaʻa cell adoptive a me nā immunotherapies ʻē aʻe a me ka hōʻemi ʻana i nā helu hāʻule i nā hoʻokolohua lapaʻau. Hoʻokomo mua ʻia ma 2020, ua loaʻa i ka z-Movi ka hoʻopiʻi ākea i nā hale hana hoʻonaʻauao a me nā biopharma a puni ka honua, me ka wikiwiki o ke kūʻai ʻana ma 2021.
He aha e lawe ʻia mai kēia ʻatikala:
- CAR-T cell immunotherapies modify T cells in the immune system to target and destroy cancer cells by genetically reprogramming T cells to make the CAR protein, by which T cells bind to, and attack, cancer cells.
- The z-Movi measures the avidity, or level of binding, between immune cells like CAR Ts, and their targets, the cancer cells, enabling researchers to identify the most potent immunotherapeutic effector cells as candidates to target and destroy specific cancer cells.
- Added Andrea Candelli, Chief Scientific Officer of LUMICKS, “We share the Kings College team’s excitement about the additional evidence shown by this paper of the critical role that cell avidity plays in uncovering and optimizing CAR T cells.
